ArticleTranslational oncology2019

A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151).

Lu Si et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.